A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms NICOLAS
- 21 Aug 2017 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 21 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.
- 21 Aug 2017 Planned number of patients changed to 78.